心房颤动患者服用利伐沙班致出血的研究进展
姚娟 - Advances in Clinical Medicine, 2023 - hanspub.org
心房颤动是较常见的一种心律失常, 目前新型口服抗凝药(NOACs) 已逐渐取代华法林,
成为房颤患者的首选治疗药物, 其中利伐沙班的使用比较普遍, 但临床上使用利伐沙班时 …
成为房颤患者的首选治疗药物, 其中利伐沙班的使用比较普遍, 但临床上使用利伐沙班时 …
[PDF][PDF] 基于文献病例的围手术期利伐沙班不良事件临床特点分析
刘雨蒙， 朱宝强， 边原， 龙恩武， 王国俊， 胡佳强 - 药物不良反应杂志 - cadrj.com
目的了解围手术期患者利伐沙班相关不良事件(AE) 的临床特点. 方法检索有关数据库(截至2022
年4 月20 日), 收集围手术期使用利伐沙班致AE 的病例报告类文献, 提取患者基本信息(国籍 …
年4 月20 日), 收集围手术期使用利伐沙班致AE 的病例报告类文献, 提取患者基本信息(国籍 …
[HTML][HTML] Atraumatic Splenic Rupture: A Notable Complication of Rivaroxaban Use
CAO Perez, K Menchaca, CX Jones, EO Perez, S Isaac - Cureus, 2023 - ncbi.nlm.nih.gov
Direct oral anticoagulants (DOACs) are well known to be associated with bleeding
complications. However, little is known about their association with atraumatic splenic …
complications. However, little is known about their association with atraumatic splenic …
Net clinical benefit of anticoagulant therapy from a neurologist's perspective: A review
AA Kulesh - Consilium Medicum, 2022 - journals.eco-vector.com
In this article the concept of" net clinical benefit"(NCB) is considered in the context of stroke,
the role of direct oral anticoagulants in secondary prevention of cardioembolic stroke and …
the role of direct oral anticoagulants in secondary prevention of cardioembolic stroke and …
Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling
S Jannati, R Patnaik, Y Banerjee - 2024 - preprints.org
Abstract Non-Vitamin K Oral Anticoagulants (NOACs) have revolutionized anticoagulant
therapy, offering improved safety and efficacy over traditional agents like warfarin. This …
therapy, offering improved safety and efficacy over traditional agents like warfarin. This …
[HTML][HTML] Spontaneous epidural hematoma induced by rivaroxaban: A case report and review of the literature
AMP Siahaan, S Tandean… - Surgical Neurology …, 2022 - ncbi.nlm.nih.gov
Background: Trauma is the most frequent reason for epidural bleeding. However, numerous
investigation had discovered that anticoagulants such as rivaroxaban could cause epidural …
investigation had discovered that anticoagulants such as rivaroxaban could cause epidural …
[HTML][HTML] Эффективность и безопасность апиксабана: что изменилось за 12 лет его использования в реальной клинической практике?
ЕП Панченко - Атеротромбоз, 2023 - cyberleninka.ru
Настоящий обзор рассматривает позиции апиксабана среди других прямых оральных
антикоагулянтов у больных фибрилляцией предсердий (ФП) и венозными тромбозами …
антикоагулянтов у больных фибрилляцией предсердий (ФП) и венозными тромбозами …
[PDF][PDF] Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial
G Witberg, I Kalka, R Kornowski, E Segal - practice, 2022 - researchgate.net
Aims The advantages of direct oral anticoagulants (DOACs) over warfarin are well
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …
Atraumatic Splenic Rupture: A Notable Complication of Rivaroxaban Use
K Menchaca, CX Jones, OP Erika, S Isaac - Cureus, 2023 - search.proquest.com
Direct oral anticoagulants (DOACs) are well known to be associated with bleeding
complications. However, little is known about their association with atraumatic splenic …
complications. However, little is known about their association with atraumatic splenic …
[PDF][PDF] Antithrombotic therap in the Netherlands: ne insights from nation ide data
Q Chen - Thromb Haemost, 2022 - scholarlypublications …
[5] Toorop MMA, Chen Q, Kruip M, van der Meer FJM, Nierman MC, Faber L, et al. Switching
from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation …
from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation …